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AbstrACt
Objective To determine the effects of yoga practice on 
subclinical cardiovascular measures, risk factors and 
neuro- endocrine pathways in patients undergoing cardiac 
rehabilitation (CR) following acute coronary events.
Design 3- month, two- arm (yoga +usual care vs usual 
care alone) parallel randomised mechanistic study.
setting One general hospital and two primary care 
CR centres in London. Assessments were conducted at 
Imperial College London.
Participants 80 participants, aged 35–80 years (68% 
men, 60% South Asian) referred to CR programmes 
2012–2014.
Intervention A certified yoga teacher conducted yoga 
classes which included exercises in stretching, breathing, 
healing imagery and deep relaxation. It was pre- specified 
that at least 18 yoga classes were attended for inclusion 
in analysis. Participants and partners in both groups were 
invited to attend weekly a 6- to 12- week local standard UK 
National Health Service CR programme.
Main outcome measures (i) Estimated left ventricular 
filling pressure (E/e′), (ii) distance walked, fatigue and 
breathlessness in a 6 min walk test, (iii) blood pressure, 
heart rate and estimated peak VO2 following a 3 min step- 
test. Effects on the hypothalamus–pituitary–adrenal axis, 
autonomic function, body fat, blood lipids and glucose, 
stress and general health were also explored.
results 25 participants in the yoga + usual care group 
and 35 participants in the usual care group completed the 
study. Following the 3- month intervention period, E/e′ was 
not improved by yoga (E/e′: between- group difference: 
yoga minus usual care:−0.40 (−1.38, 0.58). Exercise 
testing and secondary outcomes also showed no benefits 
of yoga.
Conclusions In this small UK- based randomised 
mechanistic study, with 60 completing participants (of 
whom 25 were in the yoga + usual care group), we found 
no discernible improvement associated with the addition of 
a structured 3- month yoga intervention to usual CR care in 
key cardiovascular and neuroendocrine measures shown 
to be responsive to yoga in previous mechanistic studies.
trial registration number NCT01597960; Pre- results.
IntrODuCtIOn
The practice of yoga originated in ancient 
India as a form of exercise which includes 
breath control, the adoption of bodily 
postures and meditation which aim to 
increase strength and flexibility and to aid 
physical and mental well- being.1 Yoga has 
been reported to reduce stress and depres-
sion and is thought to improve biological 
cardiovascular risk factors.2–4 However, 
despite claims of benefits, the effects of yoga 
on cardiovascular outcomes remain unclear. 
Previous systematic reviews5–12 confirm that 
investigations of the health benefits of yoga 
and underlying mechanisms have often been 
hampered by poor study design, including 
small sample sizes, inadequate adjustment for 
confounders, lack of randomisation, unsat-
isfactory masking of outcomes to assessors 
and publication bias. Also, many studies have 
been conducted in healthy young partici-
pants and it is not certain that these findings 
are generalisable to older adults with estab-
lished disease.
strengths and limitations of this study
 ► Comprehensive clinical and subclinical cardiovascu-
lar measures before and after a yoga intervention 
(plus usual cardiac rehabilitation (CR)) versus usual 
CR.
 ► Real world setting—older people following an acute 
coronary event.
 ► High level of dropout, particularly in the yoga plus 
usual CR arm.
 ► We can only assess the potential of yoga in addition 
to usual CR following an acute coronary event.
 ► Outcomes limited to 3 monthspost- intervention
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Cardiac rehabilitation (CR) has been shown to improve 
cardiovascular mortality and hospital re- admissions in 
patients with coronary heart disease (CHD).13 However, 
for myocardial infarction (MI), coronary bypass grafts 
and percutaneous coronary intervention (PCI) patients 
uptake to CR across in UK was only ~45% in 2012–2013 
with low representation of ethnic minority people.14 Yoga 
could therefore be a useful adjunct to CR.
In this UK- based randomised study (Yoga and Cardio-
vascular Health Trial (YACHT)), we hypothesised that 
yoga would be associated primarily with improvements in 
cardiovascular function and exercise capacity both chron-
ically and acutely in people eligible for CR. The chronic 
study compared cardiovascular measures at 3 months 
between two groups randomised either to usual care 
(including CR) or to usual care plus a programme of yoga 
classes. For the chronic study, where the emphasis was on 
rehabilitation following a coronary event, we focused on 
the ratio between early mitral inflow and mitral annular 
early diastolic velocity (E/e′) as the primary cardiac 
measure. E/e′ provides an estimate of left ventricular 
(LV) filling pressure,15 an aspect of LV diastolic function 
that predicts survival after MI.16 We also performed a 6 
min walk test (6MWT) as a measure of exercise tolerance 
and a 3 min step- test as a measure of cardiopulmonary 
fitness. These measures were chosen as they are repro-
ducible and safe tests which are improved by CR,17–20 and 
predict outcomes in people with CHD.16 21–23 Measures 
chosen for the acute study (before and after the first 
session of yoga) included blood pressure (BP) and heart 
rate before and after exercise as indicators of cardiovas-
cular and autonomic function which are associated with 
cardiovascular outcomes.21 23
In addition to these primary outcome measures, we 
studied a range of other cardiovascular risk factors and 
measures which might be expected to improve following 
CR and provide mechanistic insight into any beneficial 
effect of yoga; these included markers of the hypotha-
lamic–pituitary axis, measures of autonomic function, 
measures of cardiac structure and function, brachial and 
central resting and 24- hour ambulatory BP, markers of 
atherosclerosis, blood glucose and lipids and self- reported 
health, lifestyle factors and perceived stress levels.
MethODs
study population
Inclusion criteria included referral to CR programmes 
in north- west London following an acute coronary 
syndrome (MI, PCI, coronary artery bypass grafting). 
Pre- specified inclusion criteria were age between 35 
and 80 years, male or female, without comorbid disease 
or mobility limitations that would preclude participa-
tion in CR and our investigations, and, given the north- 
west London area of recruitment, able to understand 
English or Punjabi. Ethnicity was self- defined, and veri-
fied by country of birth of all four grandparents. In all, 
80 participants were recruited following discharge from 
hospital and randomised in equal numbers to the yoga 
intervention plus their standard CR programme, or to 
standard CR programme (usual care) alone. Randomisa-
tion was performed by an independent researcher using 
a standard computerised algorithm (customised Java web 
application (srub)) and stratified by ethnicity (South 
Asian and non- South Asian), gender, 5- year age group 
and rehabilitation centre. The generated sequence was 
displayed only to the user at the time of assignment to the 
yoga intervention or usual care. 75% of participants were 
recruited from referrals to CR programmes at Ealing 
Hospital in west London, with the remainder recruited 
from two primary care CR programmes in north- west 
London (Harrow and Brent (Flexi- Heart Plan)). Recruit-
ment of the planned 80 participants took place between 
October 2012 and April 2014, with the final participant 
seen for 3- month follow- up measures in July 2014.
Eligibility criteria were broadened in January 2013 and 
April 2013, respectively, with ethical approval, to include 
patients who had undergone coronary artery bypass 
grafting or who had received medical management only 
for their acute coronary event. The initial study plans were 
to recruit only patients referred to a CR programme post- 
angioplasty as treatment for an acute coronary syndrome. 
With cardiologist advice, it was felt that the earlier deci-
sion to exclude these patients based on safety grounds 
was unnecessary given the gentle and tailored nature of 
the exercises.
Patient and public involvement
Patients and public were not involved in the study design, 
conduct, results, evaluation or dissemination.
Informed written consent was obtained from all 
participants.
Yoga intervention
The yoga intervention was delivered on a twice- weekly 
group session basis for 12 weeks alongside the usual care, 
6- to 12- week CR programme. There were 24 yoga classes 
in total. Participants’ partners were invited to take part in 
each session as a method of improving adherence. The 
yoga session was designed and conducted by a teacher 
certified in yoga and CR, and included gentle exercises in 
deep relaxation, stretching, breathing, healing imagery 
and a healthy diet. A prescription of exercises with an 
accompanying DVD was provided to be performed regu-
larly at home. Each session lasted approximately 75 min, 
divided into three equal parts: breathing exercises, yogic 
poses and meditations, education and discussion (details 
in online supplemental material: YACHT study  package_ 
v1. 2. pdf). Individuals randomised to the yoga arm had 
their standard CR care delivered at a separate time to 
those randomised to usual CR (although delivered by the 
same teams), to reduce risks of contamination. Because 
the study was also designed to examine mechanisms 
underlying any beneficial effects of yoga,24 there was a 
pre- specified requirement for participants in the yoga 
+usual care group to complete at least 18 yoga classes.
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usual care
Usual care is described in the online supplemental mate-
rial (YACHT study  package_ v1. 2. pdf) and was similar in 
all centres in accordance with the UK’s National Institute 
for Health and Care Excellence guidelines (https://www. 
nice. org. uk/ guidance/ cg48, accessed 25/8/2017) and 
British Association for Cardiac Prevention and Reha-
bilitation standards25 with core components of lifestyle 
(physical activity, exercise, diet and weight management, 
smoking cessation), education, risk factor management, 
psychosocial, cardio- protective drug therapy and long- 
term management strategies. Patients and their partners 
were invited to attend once- weekly for a 6- to 12- week 
programme tailored to individual needs and including 
(1) ongoing risk factor monitoring/advice/support, (2) 
exercise sessions in a gym, led by cardiac physiologist or 
a home- based exercise programme, (3) health educa-
tion lectures (led by CR sister, pharmacist, dietitian, clin-
ical psychologist, cardiac physiologist), (4) relaxation 
sessions, (5) guidance and supervised use of the ‘Edin-
burgh Heart Manual’ (http://www. theheartmanual. 
com/ Pages/ default. aspx, accessed 26/9/2017).
Outcome measures
Chronic study: all measures performed pre-intervention and 
3-month post-intervention
Primary outcome measures
Echocardiography
Transthoracic two- dimensional and Doppler echocar-
diography were performed as previously described.26 
Transmitral flow velocity during the early filling phase 
(E) was acquired by pulsed Doppler and averaged from 
three consecutive cycles. Tissue Doppler Imaging was 
performed on the lateral and septal LV wall. Peak veloc-
ities during early diastole (e′) were averaged from three 
consecutive representative cycles. The e′ wave velocities 
measured from the lateral and septal walls were averaged. 
The primary cardiac outcome was the ratio of early filling 
and early myocardial velocity (E/e′), a non- invasive esti-
mate of LV filling pressure.15
Exercise capacity and physical fitness
Exercise capacity was measured by a 6MWT conducted 
along a 30 m straight path in an outdoor covered area 
marked clearly with the beginning and end of each lap. 
Participants wore appropriate shoes and loose- fitting 
clothing and rested in a chair for 10 min before the start 
of the test. Participants were asked to walk briskly as far as 
possible for a timed 6 min. Fatigue and dyspnoea before 
and after the walk test were assessed using the Borg scale.27
Physical fitness was measured using a Tecumseh step- 
test28 Participants were asked to step repeatedly on and 
off a step measuring 60×30×17.5 cm (length, width and 
height) for 3 min in time with a metronome set to 92 
beats per minute (bpm). This corresponds to a rate of 
energy expenditure approximately five times the basal 
metabolic rate.29 Heart rate was measured on the right 
arm immediately afterwards and then again in the seated 
position after 3 min recovery using an Omron 705CP 
device. Estimated peak oxygen consumption (peak VO2) 
was calculated based on achieved heart rate in the imme-
diate post- exercise period as described previously.28
Chronic study: secondary outcome measures
Measures of cardiac structure and function were obtained 
as described under primary outcomes above and included 
LV mass index, relative wall thickness, left atrial diameter, 
ejection fraction, mitral E/A ratio, s′ (peak velocity during 
systole) and e′ (peak velocity during early diastole).
Resting seated brachial and central BP was measured 
after 5 min seated rest using a Pulsecor BP +device 
(Uscom Ltd, Sydney, Australia)30 starting with the left 
arm and then repeated on the right arm. The average of 
the final two of three BP readings for the right arm were 
used, unless the average SBP was more than 10 mm Hg 
greater than the average in the left arm, in which case 
the left arm average readings were used as the measure 
of clinic BP. BP (standing) before, immediately after and 
after 3 min recovery following the step- test was measured 
using an Omron 705CP device on the right arm.
A Vicorder oscillometric device (SMT Medical 
Germany/Skidmore Medical UK)31 was used to measure 
carotid- femoral pulse wave velocity (PWV).
Ambulatory BP monitoring was conducted using the 
oscillometric Mobilograph device (NuMed Healthcare, 
UK)32 with an appropriately sized cuff worn on the non- 
dominant arm to record central BP and heart rate for a 
24- hour period; measurements were taken half- hourly 
between 07:00 and 21:00 hours and hourly during the 
night. Ambulatory BP and heart rate analyses included 
the daytime period from 09:00 to 21:00 hours and the 
night- time period from 01:00 to 06:00 excluding the 
waking and bedtime periods of the day as these periods 
represent times during which bed rest is inconsistent and, 
therefore, cannot be categorised reliably.33
Heart rate variability (HRV) and baroreceptor sensi-
tivity (BRS) were measured according to a published 
protocol.34 Briefly, these were measured in the recum-
bent position for a 10 min period. Beat- to- beat arterial 
BP was recorded non- invasively using a Finometer (FMS 
Amsterdam, Netherlands), and the ECG was monitored 
using a three- lead ECG. Signals were post- processed as 
described in detail previously.34 For HRV, we calculated 
the mean R- R interval, and mean spectral powers in the 
low- frequency (0.04–0.15 Hz) and high- frequency (0.15–
0.4 Hz) bands for the R- R intervals. Frequency domain 
BRS was calculated as the alpha index given by the square 
root of the ratio between averaged powers of R- R and 
systolic BP for each frequency.
Fasting bloods were analysed for glucose and lipids 
at baseline and 3- month follow- up. The HPA axis was 
assessed by salivary cortisol sampled at five points during 
the day pre- intervention and at 3- month follow- up as 
described for the acute study below. Salivary amylase, as a 
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marker of sympathetic activity, was measured at five time 
points during the day, as described for cortisol.
The full extra- cranial carotid artery was examined for 
the presence of plaque using an iE33 ultrasound machine 
(Philips) equipped with a linear- array transducer (L11_3) 
with concurrent recording of three- lead ECG over three–
five cardiac cycles. Carotid intima- media thickness (IMT) 
was measured in the distal 1 cm of the left common 
carotid artery from three longitudinal planes (anterior, 
lateral and posterior) in a region free of plaque with a 
clearly identified double- line pattern. Plaque was defined 
according to the Mannheim consensus as a focal structure 
encroaching into the arterial lumen by at least 0.5 mm or 
50% of the surrounding IMT value, or a region of IMT 
having a thickness >1.5 mm. Analyses were performed 
using a validated semi- automated programme (AMS- II).
The GeneActiv wrist- worn waterproof accelerometry 
device was fitted at the end of the pre- intervention and 
3- month follow- up visits and worn for 3 days after each 
visit. Analysis of the data was performed using a validated 
algorithm at the University of Newcastle35 to provide 
average body acceleration (metric milli g where g is 
gravity) on days with more than 16 hours of valid readings.
Self- completion questionnaires were administered pre- 
interventions and at the 3month follow- up as follows:
The international physical activity questionnaire (IPAQ) 
long version was administered and analysed according to 
the IPAQ guidelines (http://www. ipaq. ki. se/ scoring. pdf, 
accessed 25 August 2017)
A self- completion questionnaire included items 
regarding frequency of alcohol consumption, number of 
units consumed and changes in drinking habits. Similar 
questions were included regarding smoking habits. A 
food frequency questionnaire, previously used in the 
SABRE tri- ethnic cohort study36 covered the previous 7 
days.
Euroqol-5 dimension-3 Levels (EQ- 5D- 3L) (https:// 
euroqol. org/) is a standardised instrument for use as a 
measure of health outcome. It provides a simple descrip-
tive profile a visual analogue scale to indicate self- rated 
health and a health status score based on UK population 
norms (there is no set of scores based on Indian Asian 
populations).
The perceived stress 10- item self- completion scale37 
was completed together with questions regarding sleep 
quality, snoring and breathlessness at night.
Acute study: Yoga+usual care group on day of first yoga session
Primary outcome measures
BP and heart rate at rest and following a 3 min step- test 
and estimated peak oxygen consumption (peak VO2) 
measured immediately post- exercise.
Seated brachial BP was measured after 5 min rest using 
an Omron 705CP device on the right arm. BP, heart rate 
at rest and following the 3 min step- test were performed 
immediately before and after the first yoga session as 
described above for the chronic study; estimated peak V02 
was also calculated.28 29
Secondary outcome measures
Saliva samples for amylase and cortisol were collected by 
the participants at home using a Salivette ( www. salimet-
rics. com) collection kit at five time points during the day 
pre- intervention (waking, waking plus 30 min, waking 
plus 90 min, waking plus 12 hours, bedtime). For the 
acute study, waking, waking plus 12 hours and bedtime 
samples were taken on the day of the first yoga session. 
The latter two sampling points therefore occurred after 
the first yoga session. Samples were analysed using using 
indirect ELISA kits (Salimetrics Europe, Suffolk, UK).
blinding of observers
Post- processing of echocardiograms, carotid ultrasound 
scans, accelerometry, ambulatory BP, HRV and BRS, 
blood and saliva analyses were all conducted by observers 
blinded to participants’ identity and study group. Clinic 
BP, vascular measurements and anthropometric measure-
ments were conducted by clinic staff, who may have been 
aware of study group allocation, given the nature of the 
interventions.
Location where data were collected
Data were collected at the International Centre for Circu-
latory Health on the St Mary’s campus of Imperial College 
London (UK).
statistical analyses
Sample size and power
The sample size estimate was based on primary outcome 
measures for the chronic effects of yoga, that is, E/e′ 
echocardiography, 6MWT and Tecumseh 3 min step- test. 
Previous studies have reported at least half a SD benefit 
associated with yoga on both diastolic function and exer-
cise testing38 39 corresponding to a 1.1 improvement in 
E/e′,38 39 and a study in people with preserved ejection 
fraction heart failure reported more than double this 
effect (−3.2) following a 3- month exercise programme.20 
For exercise testing (the 6MWT), a distance of 40 m 
(equivalent to 0.5 SD benefit) was considered a clini-
cally significant improvement in distance walked.40 This 
improvement was exceeded in a study of CR, where 
the distance walked increased by 62 m.41 In both cases, 
these minimum important differences corresponded to 
approximately 0.5 SD . The sample size was estimated 
to detect effects of this magnitude for the three primary 
outcomes. Statistical analyses were planned to use regres-
sion modelling to adjust final measures for baseline 
differences, thus improving the precision of estimates of 
treatment effect, and shrinking the sample size require-
ment.42 The intraclass correlation coefficient (ICC) of 
the primary outcomes was ≥0.85 based on our own data 
(n=10) and other observers’.19 Using a conservative esti-
mate of ICC=0.70, and allowing for multivariable analysis, 
33 completers were required in each arm of the study to 
detect a 0.5 SD difference between groups (80% power 
and 5% significance). Thus, 40 people were recruited to 
each arm to allow for dropouts.
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Table 1 Pre- intervention characteristics by randomisation group (unadjusted)
N (%) or means (95% CI) unless 
otherwise stated Yoga +usual care Usual care
P value for 
between 
group 
difference
Pre- intervention n=40 n=40
Ethnicity: South Asian 25 (63%) 26 (65%) 0.8
Sex: male 28 (70%) 26 (67%) 0.8
Age: years 57.4 (54.1–60.7), range (35–77) 56.9 (53.8, 60.0), range (35–78) 0.8
Days since coronary event 50 (43, 57) 59 (53, 65) 0.09
Diabetes* (self report of physician 
diagnosis/anti- diabetic medication)
15 (38%) 14 (35%) 0.8
Hypertension*(self report of physician 
diagnosis)
29/37 (78%) 25/37 (68%) 0.3
Heart failure* (self report of physician 
diagnosis)
7/29 (19%) 7/29 (19%) 1.0
Antihypertensive medications* 39 (98%) 36 (90%) 0.17
Number of antihypertensive medications, 
median (95% CI)*
3 (3,3) 3 (3,3) 0.8
Beta- blockers* 33 (83%) 32 (80%) 0.8
Statins* 36 (90%) 36 (90%) 1.0
Current smoker/ex/never smoker, number* 4/14/19 1/14/24 0.3
Alcohol: never/ever drinkers, number* n=36
Never drinkers: 13
Ever drinkers: 23
n=35
Never drinkers: 10
Ever drinkers: 25
0.5
Units/week (ever drinkers)*, median (95% 
CI)
2.5 (0, 10) 4 (1, 7) 0.9
Currently employed* n=35
15 (43%)
n=32
15 (47%)
0.7
*Self- reported, n=number of responses to questionnaire item if incomplete.
Statistical methods
Chronic study: summary descriptions of continuous pre- 
intervention characteristics are shown as means (95% CI) 
for normally distributed data or as medians (95% CI of the 
median (CIM)) for non- normally distributed variables or 
as number (%) for categorical variables. Pre- intervention 
characteristics are shown for the whole study group 
(table 1) and for those who did and did not complete the 
study. (online supplementary table S1). Outcome analysis 
is restricted to those who attended the 3- month visit, and 
for the yoga group, additionally restricted to those who 
attended 18 out of the 24 yoga sessions, per protocol. A 
sensitivity analysis added four participants who did not 
complete the requisite number of yoga classes but who 
attended the 3- month study follow- up visit.
For the 3 min step- test which was conducted in three 
stages pre- and post- intervention, repeated measures 
analysis of variance (ANOVA) models were used to 
determine differences by intervention arm and timing 
(pre- intervention and 3- month follow- up for the chronic 
study) and for the acute study (pre- first and post- first yoga 
session). Repeated measures ANOVA models were also 
used for salivary amylase (log transformed) and cortisol 
measured 5 times on 3 days (yoga +usual care group) or 2 
days (usual care group).
The remaining measures were analysed using robust 
regression models,43 which are relatively efficient 
in the presence of outlier- prone error distributions. 
Three- month follow- up values were adjusted for the 
pre- intervention value of each Normally distributed 
measure, to provide adjusted mean (95% CI) values 
to allow comparison with pre- intervention observa-
tions. Where data were not normally distributed pre- 
intervention, median regression provided comparable 
3- month (median (95% CIM)) follow- up values adjusted 
for the pre- intervention value. We show between group 
differences (95% CI) and p values for all outcome 
measures. Sensitivity analyses for primary outcomes 
included adjustment for informative baseline covariates 
(age, sex, diabetes, body mass index plus height for the 
6MWT). Between- group and within- group differences in 
categorical secondary outcome measures were tabulated 
and tested using the χ2 test.
For HRV and BRS, we conducted sensitivity analyses 
that excluded the few participants who were not receiving 
beta- blocker medication.
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Statistical analyses were performed using STATA V.15 
software.
resuLts
In all, 80 participants were recruited and randomly 
assigned in equal numbers to the yoga plus usual care 
and usual care groups. Pre- intervention, average age was 
57.1 (95% CI: 54.9 to 59.4), 68% were men and 64% 
were of South Asian origin. Diabetes was present in 36%. 
The majority were receiving statins (90%) and/or anti- 
hypertensive medication (95%) (table 1). Consistent with 
current practice in the UK, 91% had received PCIs.
In all, 35 participants in the usual care arm (63% South 
Asian) and 25 participants in the yoga arm (59% South 
Asian) completed the study. Greater loss to follow- up 
occurred in the yoga group, mostly due to unwillingness 
to continue with yoga classes—participants frequently 
citing ill health as a reason, although one participant with-
drew from the study because of return to work (online 
supplementary figure S1). Characteristics of those who 
completed the study and those who dropped out were 
similar pre- intervention (online supplementary table S1). 
In addition to overall study dropout, several participants 
declined or were unable to undergo exercise testing either 
pre- or post- intervention, mostly due to mobility problems 
or elevated BP (reasons are listed under table 2).
No adverse events were reported. There was minimal 
change in the number and type of medications prescribed 
over the 3- month course of the study (table 1 and online 
supplementary table S1).
Chronic study
Primary outcomes
LV diastolic function
At 3- month follow- up, E/e′ improved in both groups, but 
there was no evidence of yoga- related additional benefit 
in diastolic function (E/e′: between- group difference: 
yoga minus usual care:−0.40 (−1.38 to 0.58) (adjusted for 
pre- intervention values) p=0.4 (table 2)
6 Min walk test
The total distance walked increased in both groups at 
3- month follow- up, but there was no evidence of yoga- 
related additional benefit (between group difference yoga 
minus usual care: −7 (−39, 26) m, p=0.7; table 2). Distance 
walked per minute also increased post- intervention to a 
similar level in both groups and there was no additional 
advantage related to yoga in the total number of minutes 
walked or in levels of fatigue and breathlessness (table 2)
3 Min step-test
The results of the 3 min step- test at 3- month follow- up 
suggested some moderate improvements in immediate 
post- exercise BP, heart rate and peak VO2 in both groups 
at follow- up, but there was no evidence of additional 
benefit associated with yoga (table 2).
Secondary outcomes
Other vascular measures
There was no evidence of yoga- related additional bene-
fits for measures of clinic and ambulatory measures 
of brachial and central SBP at follow- up. Both groups 
showed improvements in resting brachial DBP and in 
resting central SBP. PWV was similar in the two groups at 
follow- up (table 3).
Carotid IMT
There was no evidence of additional yoga- related benefit 
on carotid IMT levels at 3 months (table 3).
HPA axis
Salivary cortisol, as a marker of the HPA, decreased 
throughout the day in both groups pre- intervention and 
at 3- month follow- up. There was no evidence of addi-
tional yoga- related benefit compared with usual care 
alone (table 3)
Autonomic function
There was no evidence of additional yoga- related benefit 
compared with usual care alone on markers of HRV, BRS 
at 3- month follow- up and salivary amylase (table 4).
Metabolic measures
There was no evidence of additional yoga- related benefit 
compared with usual care alone at 3- months follow- up 
in glucose, total cholesterol and low- density lipoprotein 
(LDL) cholesterol (table 3).
Anthropometrics
Both groups had slightly lower waist to hip ratios at 
follow- up than at baseline, but with no evidence of yoga- 
related additional benefit compared with usual care 
alone. (table 3).
Other measures
Accelerometry over 3 days showed that the usual care 
group modestly increased levels and the yoga group 
maintained levels of physical activity during the follow- up 
period. Self- reported physical activity (IPAQ) increased 
in both groups, with no evidence of additional benefit 
from yoga compared with usual care alone (table 3).
Similarly, the EQ- 5D- 3L measures of health status or 
self- rated health at follow- up did not show any convincing 
evidence of a treatment effect at follow- up, although 
there was a small increase in EQ- 5D- 3L health status based 
on UK population norms in people randomised to yoga 
compared with those receiving usual care. The EQ- 5D- 3L 
self- rated health thermometer improved to equal extents 
in both yoga and usual care groups over the 3- month 
period. The yoga group had lower stress scores than the 
usual care group both pre- intervention and at follow- up 
and there was no convincing evidence of change in stress 
score in either treatment group (table 3).
There were very few current smokers at baseline or 
follow- up and there were no between- group differences 
or within- group changes. There were no between- group 
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differences or significant within- group changes at 
follow- up in self- reported hours and quality of sleep, in 
alcohol consumption or in consumption of fresh fruit 
and vegetables (not shown).
sensitivity analyses
Sensitivity analyses of the primary outcomes which 
added those four participants who did not complete 18 
yoga classes, but who did attend the 3- month follow- up 
clinic, did not alter findings. Likewise, exclusion of the 
few people who were not receiving beta- blocker medi-
cation did not alter the findings for HRV, BRS and sali-
vary amylase. Additional adjustment of primary outcome 
measures for selected informative baseline covariates 
(age, sex, diabetes, body mass index (and height for the 
6MWT)) did not alter conclusions, for example, adjusted 
between group difference in E/e′ was −0.18 (−1.28, 0.92) 
compared with −0.38 (−1.38, 0.58) when adjusted only 
for baseline E/e′. The 3 min step- test and 6MWT find-
ings were little changed on adjustment for these baseline 
covariates
Acute study (yoga arm only)
A 3 min step- test was performed before and after the first 
yoga session and BP was measured pre- exercise, imme-
diately post- exercise and 3 min post- exercise. In all, 27 
participants undertook this test, three refused, eight were 
unable to undertake exercise testing due to mobility prob-
lems and/or shortness of breath, one had unstable angina 
and in one case equipment failure resulted in loss of data. 
There was no convincing evidence of an acute effect of 
yoga on BP, heart rate or estimated peak VO2 (table 5a). 
Salivary cortisol and amylase were similar at the waking 
+12 hours and bedtime periods after the first yoga session 
compared with pre- intervention levels (table 5b).
DIsCussIOn
We show no additional cardiovascular benefit of a 
3- month yoga intervention over and above usual care 
including CR in a randomised trial in people who had 
experienced an acute coronary event. Specifically, there 
was no additional impact on our co- primary outcomes of 
E/e′ or exercise capacity, nor on a wide range of other 
secondary outcomes including measures of cardiac struc-
ture and function, brachial, central and ambulatory 
BP, BP and heart rate responses to exercise, estimated 
peak VO2, carotid IMT, blood lipids and glucose, obesity 
measures including fat mass and body mass index, self- 
reported physical activity levels, distance walked in the 
6MWT alcohol, smoking and dietary intake.
Of the cardiovascular risk factors studied to date, BP 
appears the most consistently beneficially affected by 
yoga,8 10 44 with reports that reductions in BP are similar 
to those obtained by anti- hypertensive medication.45 
However, a community- based crossover study in India of 
non- pharmacological interventions showed that physical 
exercise (brisk walking for 50–60 min, 3–4 days a week 
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Table 5a Acute study, primary outcomes: immediate post- exercise results following a 3 min step- test, before and after (same 
day) the first yoga class
n=27
Before first yoga 
session
Mean (95% CI)
After first yoga 
session:
Mean (95% CI)
Post–pre- first yoga 
session difference 
mean (95% CI)
P value for 
comparison 
between 
before and 
after first 
yoga session
Resting seated
Systolic blood pressure, mm Hg 132 (128 to 136) 133 (129 to 136) 1 (−9 to 11) 0.9
Diastolic blood pressure, mm Hg 78 (77 to 81) 79 (77 to 81) 1 (−5 to 7) 0.7
Heart rate, bpm 69 (67 to 71) 68 (66 to 70) −1 (−8 to 6) 0.9
Immediately post- step- test, standing
Systolic blood pressure, mm Hg 161 (157 to 164) 156 (148 to 163) −5 (−15 to 6) 0.4
Diastolic blood pressure, mm Hg 80 (78 to 82) 80 (78 to 82) −1 (−7 to 5) 0.8
Heart rate, bpm 92 (90 to 94) 88 (86 to 90) −3 (−10 to 4) 0.4
Peak VO2, mL/min/kg (n=24) 36.9 (33.4 to 40.4) 38.9 (35.4 to 42.4) 2.0 (−0.2 to 4.1) 0.07
3 min post- step- test, seated
Systolic blood pressure, mm Hg 133 (129 to 136) 135 (131 to 139) 2 (−8 to 13) 0.7
Diastolic blood pressure, mm Hg 78 (76 to 80) 79 (77 to 82) 1 (−5 to 8) 0.6
Heart rate, bpm 72 (70 to 74) 69 (67 to 71) −3 (−10 to 4) 0.4
*12 participants did not participate in the step- test both before and after the first yoga session due to: mobilityproblems±shortness of breath 
(n=3), refused (n=3), frailty (n=2), unstable angina (n=1), other (high blood pressure/dizziness/weakness on left side/restricted movement; n=3). 
Blood pressure readings were unavailable for one participant due to equipment failure.
Table 5b Acute study: secondary outcomes: salivary amylase and cortisol: pre- intervention and day of first yoga class
Pre- intervention
Means (95% CI)
Day of first yoga session
Means (95% CI)
Post–pre- first yoga session 
difference
Means (95% CI)
n=32* n=32*
Cortisol, nmol/L
Waking 12.7 (11.0 to 14.4) 15.4 (12.8 to 17.9) (pre- yoga) N/A
12 hours after waking 3.6 (1.8 to 5.4) 4.4 (1.7 to 7.0) (post- yoga) 0.5 (−3.5 to 4.5)
Bedtime 3.4 (1.6 to 5.2) 3.0 (0.3 to 5.7) (post- yoga) −0.3 (−4.3 to 3.7)
Amylase, log 
microunits/L
Waking 4.40 (4.23 to 4.57) 4.28 (4.02 to 4.54)
(pre- yoga)
N/A
12 hours after waking 4.66 (4.47 to 4.84) 4.58 (4.32 to 4.85)
(post- yoga)
−0.08 (−0.54 to 0.38)
Bedtime 4.60 (4.42 to 4.78) 4.74 (4.47 to 5.01)
(post- yoga)
0.13 (−0.32 to 0.59)
*Eight participants were unable to provide adequate saliva samples pre- recruitment and on the day of the first yoga session. N/A, not 
available.
for 8 weeks) was a more effective method of reducing BP, 
compared with yoga training or salt reduction, which both 
had similar smaller effects.46 More recently, a community- 
based randomised controlled trial in Sweden found no 
evidence of reductions in resting BP due to a 3- month 
yoga intervention47—similar to our findings.
The acute effects of yoga on cardiovascular responses 
to exercise have not been well studied, although a study 
of 33 female college students in the USA reported that 
reduction in salivary cortisol following 1- hour sessions of 
power yoga, stretch yoga or control (watching an educa-
tional movie for 1 hour) were similar between inter-
ventions.48 We saw little change in cortisol levels in the 
either group at 3- month follow- up or in the yoga group 
although later in the day following the first yoga session. 
At 3- month follow- up, improvements in heart rate and 
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estimated peak VO2 were seen in both groups compared 
with the pre- intervention levels but there was no evidence 
of benefit from yoga. Likewise, both groups improved 
in terms of distance walked in the 6MWT at 3 months 
of follow- up but addition of yoga to usual care had no 
effect compared with usual care alone. An USA- based 
study in heart failure patients reported a 0.5 SD improve-
ment in exercise tolerance (+17% in nine patients with 
heart failure enrolled to an 8- week yoga programme and 
−7% in 10 patients enrolled to receive standard medical 
therapy alone39). The same study also showed greater 
improvements in quality of life in the yoga group (scores 
improved by 26% in the yoga group and by 3% in the 
standard medical therapy group39). Heart failure was 
relatively infrequent in our study participants (less than 
20% reported previously diagnosed heart failure and the 
median ejection fraction was 54% which is only slightly 
below the reported lower limit of the normal reference 
ranges for male and female Europeans (55.8% in men 
and 57.3% in women)49); but whether this can account 
for differences between study findings must remain 
speculative.
Measures of HRV may be more sensitive to subtle 
changes than traditional tests of autonomic function, 
and improvements associated with yoga training or tai chi 
have been observed in systematic reviews for a number of 
parameters50 51; however, we found little evidence for any 
yoga- related benefits in these parameters over 3 months.
Yoga has been variously shown to reduce fasting glucose 
and glycated haemoglobin, insulin, total and LDL choles-
terol, triglyceride and weight, even in those without 
diabetes,52 although not all studies have shown a consis-
tent benefit across these risk factors.7 53 54 We found no 
evidence of yoga- related benefits in blood lipids, glucose 
or obesity measures. Statin use was high (89%+) in both 
our study groups which may limit the measurable effect of 
interventions on lipid levels.
A 3- month multimodality intervention including 
yoga improved stress management, stress, depression, 
hostility and quality of life in a large group of patients 
with CHD, although this study lacked a control arm.55 56 
While we showed little change in perceived stress and did 
not measure stress management, depression or hostility, 
there was a small improvement in the EQ- 5D measure of 
health status based on UK population norms in the yoga 
group in our study although the 95% CI of the difference 
included the null.
Impacts of yoga on subclinical and clinical cardiovas-
cular disease have been inconsistently studied, making it 
difficult to place in context our findings of no evidence of 
improvement in E/e′ due to yoga, although E/e′ appeared 
lower in both groups at follow- up compared with baseline. 
Although our participants had pre- intervention levels of 
E/e′ that could be considered ‘normal’, it is important to 
note that increased cardiovascular risk increases linearly 
across the entire range of E/e′ and there is evidence that 
exercise can improve diastolic function even in healthy 
individuals.57 Yoga in comparison with walking has been 
reported to improve cardiac function in older hyperten-
sive individuals in India58 and, in a high- risk subgroup of 
older individuals in the USA a multimodality intervention 
including yoga reduced carotid IMT to a greater extent 
than usual care or dietary and exercise advice53; however, 
no effect of the intervention was seen in the whole group, 
and numbers in the high- risk subgroups were small. 
Although our study was not designed or powered for long- 
term follow- up of cardiac events, we note that a multi- 
modality intervention including yoga, in a group of 35 
participants, showed reduced numbers of cardiac events 
and progression of atherosclerosis to a greater extent in 
the lifestyle intervention arm compared with the control 
arm over 5 years of follow- up.59 Similarly in 123 angio-
graphically documented patients with moderate to severe 
coronary artery disease, the Mount Abu Open Heart Trial 
of a multimodality intervention including Rajyoga medi-
tation showed a trend towards regression of coronary 
lesions and a reduction in coronary events in those most 
adherent to the programme compared with those least 
adherent.60
As noted earlier, there is a general difficulty in 
comparing studies due to the wide variation in study 
designs and populations. A recent systematic review of 
306 randomised controlled trials of yoga found that 91% 
reached positive conclusions.61 The authors confirmed 
difficulty in comparison of results across all trials, due to 
the common lack of a priori defined primary outcomes 
and appropriate group comparisons.
strengths and limitations
This is the first study to our knowledge to adopt a 
comprehensive approach to measuring cardiovascular 
clinical and subclinical outcomes in response to a yoga 
intervention. It is also unusual in studying outcomes in 
a real- world setting in an older group of people eligible 
for CR following an acute coronary event; however, the 
trial was not designed to establish whether yoga may have 
benefits in terms of cardiovascular events or angina, for 
this much larger studies would be required. Also for some 
outcomes, such as IMT, it is likely that 3 months is too 
short a time to observed substantial regression. Dropout 
in the yoga arm of the study exceeded that in the usual 
care arm (25 and 35 completed the study, respectively), 
possibly reflecting the dual burden of attending both 
yoga training and usual CR. Consequently, the study will 
not have achieved the planned statistical power, as we had 
estimated a requirement for 33 in each group to enable 
detection of a 0.5SD difference in the primary outcomes, 
although given the measured effect sizes and CIs, we 
believe if there are benefits of yoga on the measured 
outcomes, they are likely to be small. We did not adjust 
for multiple testing as we had identified a priori relevant 
primary outcomes for the trial, but in practice adjust-
ment for multiple testing would not have altered our 
interpretation given the null findings. CR is standard 
care following an acute coronary event in the UK, thus 
ethical reasons prevented comparison of yoga- based CR 
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directly with usual CR alone—hence, this study cannot 
tell us about the potential of yoga as an alternative to 
traditional CR. Our findings also cannot be generalised to 
other conditions that may benefit from CR, such as heart 
failure, post- valve replacement, stable angina pectoris or 
symptomatic peripheral artery disease.25 It should also be 
noted that our study was designed as a mechanistic study 
to complement a larger (around 4000 patients) Indian 
Council for Medical Research and Medical Research 
Council, UK- funded study of yoga as a primary method of 
CR in India, which may shed light on some of the issues 
discussed above.24
COnCLusIOn
In this small UK- based randomised mechanistic study 
with 60 completing participants (of whom 25 were in 
the yoga +usual care group), we found no discernible 
improvement associated with the addition of a structured 
3- month yoga intervention to usual CR care in any key 
cardiovascular or neuroendocrine outcomes shown to be 
responsive to yoga in previous mechanistic studies.
We suggest that usual care CR programmes in the UK, 
which include exercise, and optimisation of medical 
therapy may leave little additional scope for added bene-
fits from a further intervention such as yoga.
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